<DOC>
	<DOCNO>NCT02206854</DOCNO>
	<brief_summary>For previous clinical trial , R-flurbiprofen prepare tablet form . In study R-flurbiprofen , available gelatine capsule . This study aim show bioavailability R-flurbiprofen administer gelatine capsule . The serum availability determine analysis pharmakokinetic ( pK ) -blood sample different time point . To assess safety administer capsule adverse event document . Analysis lipid signal molecule plasma do assess role molecule variable therapeutic effect .</brief_summary>
	<brief_title>Bioavailability , Pharmacokinetics Tissue Distribution R-flurbiprofen Capsules Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Flurbiprofen</mesh_term>
	<criteria>Healthy subject age 18 65 year Body mass index ( BMI ) 18.5 und 30 kg/m2 Subject judge good health base medical history , physical examination , vital sign measurement , laboratory safety test Subject evidence clinically significant abnormality echocardiogram ( ECG ) perform screen visit and/or prior administration study drug NonSmoker Subjects provide informed consent Subjects know hypersensitivity study medication Subjects experience asthma , urticaria , allergictype reaction take aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) Subjects history peptic ulcer disease and/or gastrointestinal bleeding Pregnant woman ( pregnancy rapid assay require woman childbearing potential ) , woman currently breastfeed , intention breastfeed History evidence active malignancy within 24 month prior entry . Subject history fainting blood draw . Subject major surgery , donate lose 1 unit blood ( approximately 500 ml ) last 4 week Subject currently regular user ( include `` recreational use ) illicit drug history drug ( include alcohol ) abuse within approximately 2 year . Active history drug abuse , Chronic acute renal , hepatic metabolic disorder Participation clinical study within 30 day prior screen Subjects immunodeficiency establish acquire immunodeficiency syndrome . Subject unable refrain anticipates use medication , ( include prescription nonprescription drug herbal remedy ( St. John 's Wort ) begin approximately 2 week ( 5 halflives ) prior administration initial dose study drug followup visit . Subject history illness , opinion study investigator , might confound result study pose additional risk subject participation study . There concern investigator regard safe participation subject study reason , investigator considers subject inappropriate participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Pharmakokinetic</keyword>
	<keyword>capsule</keyword>
	<keyword>R-Flurbiprofen</keyword>
</DOC>